Investors & Media

Bio Details

Stuart A. Arbuckle

Stuart A. Arbuckle has served as a director of ImmunoGen since 2018. Mr. Arbuckle has more than 30 years of experience in building biopharmaceutical commercial organizations and has served as Vertex’s Executive Vice President and Chief Commercial Officer since 2012, leading the successful global launches of Kalydeco® and Orkambi®. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., most recently serving as Vice President and Regional General Manager overseeing the expansion of the company’s presence in Japan, Asia, the Middle East, and Africa. As Vice President and General Manager of Amgen’s Oncology Business Unit, he was responsible for sales and marketing efforts for Aranesp®, Neulasta® and NEUPOGEN®, and led the successful launches of XGEVA® and Nplate®. Prior to Amgen, Mr. Arbuckle held commercial roles of increasing responsibility at Celltech Pharmaceuticals and GlaxoSmithKline. He also previously served as a member of Cerulean Pharma’s Board of Directors. He is currently a national board member of the Cancer Support Community, a member of the Executive Committee and Health Section Governing Board for the Biotechnology Innovation Organization (BIO), and is co-chair of the BIO Standing Committee on Access and Value. Mr. Arbuckle has a degree in pharmacology and physiology from the University of Leeds in the United Kingdom.